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Introduction
With over 6 million Americans living with Alzheimer’s disease
(AD) in 2021, AD is the most common neurodegenerative
disease that eventually leads to a loss of cognition. The
accumulation of proteins including tau tangles and amyloid
plaques in the brain leads to a cognitive decline and symptoms
of dementia by catalyzing neuronal cell death. These
accumulations of proteins and their underlying mechanisms can
occur years prior to an onset of symptoms, which makes it
possible to have individuals with asymptomatic Alzheimer’s
disease. For this project, I compared, through proteomic data
analysis of data acquired by Johnson et. al., significant changes
in protein abundance between control brain samples and
asymptomatic Alzheimer’s brain samples and identified
proteins and functional processes that may be involved in the
initiation of the asymptomatic stage of Alzheimer’s disease.

Results

Myelination

Figure 2. Volcano plot depicting the significantly increasing proteins,
CNTNAP1, PLP1, CNTN2, QKI, SOD1, JAM3, that are involved in the
myelination of neuronal cells affected by the asymptomatic stage of
Alzheimer’s disease.

DNA damage and oxidative stress response

Figure 3. Volcano plot indicating significantly increasing proteins that
recognize damage to the DNA helix (COPS6, COPS3, PARP1) and that
manage the rate and frequency of oxidative stress induced neuronal cell
death (APP, LANCL1, PARP1). PARP1 is identified as an increasing
protein that is involved in both biological functions.
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Figure 4. GO analysis of the negatively differing significant proteins
between control samples and asymptomatic Alzheimer’s disease
samples (proteins that increase in abundance in the asymptomatic
Alzheimer’s samples). Six proteins dealing with myelination increased
in the asymptomatic Alzheimer’s samples. These six proteins,
increased at a fold enrichment of 15.14 from an expected value of 0.4.
Myelination proteins are associated with formation and maintenance
of myelin sheaths around neurons, suggesting an increase in the cell’s
effort to maintain the neuronal pathways through increased
myelination during the progression of Alzheimer’s disease.
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The first step in the progression of Alzheimer’s disease is
the asymptomatic stage. Analysis of the changing proteins
at this stage relative to a healthy patient can give insight
into what cellular changes lead to onset of disease.
Proteomics allow for quantification and comparison of
proteins that are changing between a control brain sample
and a brain sample with asymptomatic Alzheimer’s disease.
Significantly more proteins increase in abundance in the
asymptomatic Alzheimer’s samples compared to the control
samples, supporting the idea that the early progression of
Alzheimer’s is due to at least some level of protein
accumulation and that even at the beginning the rate of cell
death is increasing. Further analysis into the proteins that
are significantly changing can then be used to identify
enriched biological functions in asymptomatic AD. In the
case of asymptomatic AD, these processes include proteins
dealing with myelination, DNA damage and oxidative
repair. The increase in these proteins shows that cells are
attempting to maintain myelination and slow the rate of
cellular death in the asymptomatic stage, long before
presenting with symptoms. The development of more
proteomic analysis into the beginning stages of
asymptomatic AD shows potential to reveal more proteins
and functions that are increasing at the onset of the disease.
Alzheimer’s disease can currently only be treated by the
management of symptoms, and an increased understanding
of these changes leading to an asymptomatic stage of AD
will help in early detection and intervention.
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Figure 1. The data that was used in the proteomics analysis was acquired from
asymptomatic Alzheimer’s brain samples and control brain samples. TMT based
mass spectrometry was used to measure the relative abundance of proteins. These
in-lab procedures were done by Johnson et. al. and published as public data. In our
process of proteomic data analysis, we filtered this public data for significance
meaning that there was a substantial difference in protein abundance between the
control and asymptomatic samples. These significant proteins were then used in a
GO analysis to show the biological implications of their change in abundance. This
can help identify the neurological changes that occur as a result of the significant
changing abundances of these specific proteins.
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Conclusions

Figure 5. GO analysis of the negatively differing significant proteins
showed three proteins that effect DNA damage recognition and
nucleotide-excision repair. It also showed three proteins that effect the
regulation of stress induced neuron death increasing in the
asymptomatic Alzheimer’s samples comparative to the control samples.
These two groups of proteins recognize damage to the DNA helix and
modulate the frequency of oxidative stress induced neuronal death
respectively. The three proteins that increase DNA damage recognition,
COPS6, COPS3, PARP1, increase at a fold enrichment of 34.89 from
an expected value of 0.09. The three proteins that increase the
regulation of neuronal death through oxidative stress, APP, LANCL1,
PARP1 increase at a fold enrichment of 32.10 from an expected value
of 0.09. The protein PARP1 increases in both categories indicating the
implication of DNA damage as the consequence of neuronal death. The
increase of these proteins depicts the cellular response to neuronal
death.
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